Skip to main content
MyDeficiencies

Cholecalciferol

Vitamin D3 secosteroid, prohormone (prescription strength)

Also sold as Decalcitrol, D3-50.

Analyze another medication Medication directory

Findings for this medication

Research about this medication, graded for how strongly each finding can be attributed to it. Nothing here describes your own levels.

Cholecalciferol is an unusual entry for this protocol because the drug being reviewed is itself the nutrient. It is not metabolized by, and does not induce or inhibit, hepatic drug-metabolizing CYP450 enzymes in the sense this protocol usually screens for; instead it is the substrate of a dedicated two-step activation pathway, hepatic 25-hydroxylation (principally CYP2R1, with a secondary contribution from CYP27A1) to calcifediol, then renal 1-alpha-hydroxylation (CYP27B1) to the active hormone calcitriol, with catabolism via CYP24A1. That two-step requirement is the single most important pharmacokinetic fact distinguishing cholecalciferol from its sibling drugs already reviewed in this project: calcitriol is the terminal hormone with a 5 to 8 hour half-life and titratable, fast-acting pharmacology, while cholecalciferol is a fat-soluble precursor that is stored extensively in adipose tissue and released slowly, so its labeled onset of action lags 10 to 24 hours and its effects can persist two or more months after a course is stopped. This dossier does not grade "vitamin D status" as something cholecalciferol depletes or restores, since that would be circular; it grades cholecalciferol's real, drug-specific interactions with other nutrients and physiological systems at the supraphysiologic doses this prescription form is actually used at.

Vitamin D3 secosteroid, prohormone (prescription strength) · ATC A11CC05 · also sold as Decalcitrol and D3-50 and generic 50 and 000 IU cholecalciferol and generic high dose D3 drops · reviewed 2026-09-28. This describes research about the medication. It does not say anything about your own levels or health.

How to read the evidence grades

These colours describe how strongly a finding can be attributed to the medication in the research. They are not a severity score and they say nothing about your own health.

Grades describe how strongly a finding can be attributed to Cholecalciferol in the research — not how common it is, how serious it would be, and not anything about you personally.

Red — Severe
Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence.
Orange — Moderate
At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.
Yellow — Low
Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction.
Not graded — disclosed evidence gap
Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result.Source definition: Not gradeable under the rules above because nothing has been measured. Published as a documented gap, never as reassurance that there is no effect.

What the research found

Calcium, hypercalcemia

Red — Severe

See study details

Cholecalciferol directly and predictably raises serum calcium by increasing intestinal absorption once activated; at the doses used in prescription-strength regimens this is a real, repeatedly documented, dose-dependent toxicity, not a deficiency effect, and supplementation of more calcium or vitamin D is the hazard here, not the remedy.

Full detail and limits

What the grade means here: Two or more independent Tier A sources, this drug in the cohort, the nutrient directly measured, consistent direction, clinically meaningful magnitude, a named mechanism, no substantial contradicting Tier A evidence. RED, excess direction

Limits on what this shows

  • Key negative/null findings: No source found in this review contradicts the direction of this effect; appropriately dosed, monitored regimens for diagnosed deficiency do not typically produce hypercalcemia, which is why the labels require the two-weekly calcium and phosphorus checks rather than treating the risk as purely theoretical.
  • At-risk subgroups: Prolonged high-dose regimens continued past correction of deficiency, concomitant thiazide diuretics, concomitant calcium supplementation or additional vitamin D sources, granulomatous disease (sarcoidosis, tuberculosis, where macrophages can produce calcitriol outside normal renal regulation), primary hyperparathyroidism, renal impairment, and infants, pregnant women, or people with liver disease, for whom the reviewed dietary-supplement-style label advises against use.
  • Counter-evidence on record: None found contradicting direction or mechanism; the case-report literature is consistent that this is a real, monitorable, dose-dependent risk rather than a purely theoretical one.

Regulatory status

Both prescription-strength labels reviewed list hypercalcemia, malabsorption syndrome, and "abnormal sensitivity to the toxic effects of vitamin D" as contraindications, and require blood calcium and phosphorus determinations at least every two weeks, or more frequently if necessary, during use; thiazide diuretic co-therapy is separately flagged as raising hypercalcemia risk.

Population evidence

A published review of case reports (Nutrients, 2018) covering 13 source articles and more than 82 individual cases of vitamin D toxicity from overcorrection found serum calcium ranging from 11.1 to 23.1 mg/dL against a normal range of roughly 8.4 to 10.2 mg/dL, with doses spanning prescribed 50,000 IU per day regimens continued about one year, single injections of 600,000 IU, cumulative intramuscular exposures of 6,000,000 IU over two weeks, and manufacturing-error pediatric exposures of 266,000 to 800,000 IU per day; symptoms included vomiting, dehydration, altered mental status, polyuria, polydipsia, nephrocalcinosis, and acute kidney injury in severe cases. Cholecalciferol is directly the agent described in every case cited. Tier A.

Mechanism

Named: once hydroxylated to the active hormone, vitamin D receptor signaling upregulates intestinal transcellular calcium absorption and increases osteoclastic bone resorption; this is the same genomic mechanism that makes vitamin D therapeutically necessary in deficiency and toxic in excess, and it is explicit in both labels reviewed.

Counter-evidence held on record

This is an excess/retention risk from the drug's own intended pharmacology once activated, not a nutrient deficiency. Do not add calcium or additional vitamin D sources on top of prescription-strength cholecalciferol without prescriber-directed monitoring; correction of hypercalcemia is stopping or lowering the dose, not further supplementation.

No entry met the orange threshold

Orange — Moderate

See study details

This tier is printed empty deliberately, per this protocol's rule that an empty tier is itself a finding.

Full detail and limits

What the grade means here: At least one Tier A source with this drug in the cohort showing a real but bounded deficit: an exposure window, a subgroup, low frequency, or a functional rather than circulating deficit.

Limits on what this shows

  • What would fill this tier: A Tier A study isolating cholecalciferol monotherapy, not combined with vitamin K2, calcium, or magnesium co-supplementation, that demonstrated a bounded, subgroup-specific harmful deficit, for example confirmed primary-study (not meta-analysis subgroup summary) evidence of hemoglobin decline in a defined chronic kidney disease population attributable to cholecalciferol itself, or a controlled trial directly demonstrating clinically meaningful serum magnesium decline with high-dose cholecalciferol monotherapy.

Why empty

Every drug-specific deficit finding for cholecalciferol strong enough to reach Tier A in this review was either severe and consistent enough to grade red (calcium), or was a reverse-direction protective or mixed-direction finding that this project's grading conventions cap at yellow regardless of evidence volume, consistent with how the sibling calcitriol and paricalcitol dossiers in this project treated similarly protective Tier A and Tier B findings. No source found in this review isolated cholecalciferol alone, as opposed to a combination regimen, showing a real but exposure- or subgroup-bounded deficit at Tier A strength.

Vitamin K, calcium-deposition interplay, combination-trial evidence only

Yellow — Low

See study details

A real, mechanistically grounded hypothesis, that vitamin D-driven calcium mobilization needs vitamin K-dependent carboxylation of matrix Gla protein and osteocalcin to be directed to bone rather than soft tissue, has genuine randomized trial support when D3 and K2 are combined, but no source in this review isolated cholecalciferol's independent contribution or proved that cholecalciferol alone, without K2, causes vascular calcification.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, mechanism plus combination RCT, direction unresolved

Limits on what this shows

  • Key negative/null findings: The trial's overall primary endpoint was not statistically significant (P equals 0.089), a genuine null at the full-cohort level; the benefit was confined to a prespecified high-baseline-calcification subgroup, and because there is no vitamin-D-alone comparator arm in this trial, it cannot show whether cholecalciferol alone accelerates calcification, whether K2 alone is protective independent of D3, or whether the combination's modest subgroup benefit reflects K2's contribution, D3's contribution, or both together.
  • At-risk subgroups: Not established specifically for cholecalciferol; the trial population was elderly men with pre-existing elevated calcification scores, which is also the population in which this hypothesis is most often raised clinically.
  • Counter-evidence on record: The null overall primary result is itself counter-evidence against a strong, unqualified version of the "vitamin D without K2 causes calcification" claim; this review found no cholecalciferol-alone arm in any trial that could test the claim more directly, which is the central limitation on grading this any higher than yellow.

Regulatory status

Not addressed in either prescription-strength label reviewed; no vitamin K interaction is labeled for cholecalciferol.

Population evidence

Multicenter, double-blind, randomized controlled trial across four Danish hospitals (the AVADEC trial substudy, reported in JACC: Advances), 304 participants completing (155 placebo, 149 intervention), elderly men with aortic valve or coronary calcification scores above the 90th percentile, no prior ischemic heart disease. Intervention was vitamin K2 720 mcg per day plus vitamin D 25 mcg (1,000 IU) per day for 24 months against placebo. Coronary artery calcification progressed 254 Agatston units in placebo versus 203 units in the combined-supplement arm, a difference that did not reach significance overall (P equals 0.089), but in the subgroup with baseline calcification of 400 Agatston units or more, progression was 380 units in placebo versus 288 units with treatment (P equals 0.047). Cholecalciferol was directly administered, but only as part of the combined K2 plus D3 regimen, not as an isolated arm.

Mechanism

Named for the hypothesis, though not proven for cholecalciferol in isolation: vitamin D receptor signaling raises circulating calcium and upregulates osteocalcin and other Gla-domain proteins; those proteins require vitamin K-dependent gamma-carboxylation, catalyzed via matrix Gla protein among others, to bind calcium correctly, and NIH's own vitamin K reference material states matrix Gla protein "might help reduce abnormal calcification" in vascular tissue.

Counter-evidence held on record

Do not present this as proof that prescription-strength cholecalciferol requires co-administered vitamin K2, or that skipping K2 will cause vascular calcification; the only trial evidence located is a combination regimen against placebo with a null overall primary result, not a test of cholecalciferol alone.

Magnesium, cofactor utilization theory, direction empirically runs the other way

Yellow — Low

See study details

Magnesium is a documented required cofactor for the hydroxylase enzymes that activate and catabolize vitamin D, giving a real mechanistic basis for concern that high-dose cholecalciferol therapy could increase magnesium utilization, but the best empirical evidence located in this review shows the relationship running predominantly the other way, baseline magnesium status governing the vitamin D response, and this review found no controlled trial demonstrating that cholecalciferol supplementation itself lowers serum magnesium.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, mechanism only, direction contested

Limits on what this shows

  • Key negative/null findings: A separate randomized, double-blind, placebo-controlled trial (78 completers, adults with overweight or obesity, 12 weeks) directly compared 1,000 IU cholecalciferol alone, 1,000 IU cholecalciferol plus 360 mg magnesium glycinate, and placebo; it reported successful vitamin D repletion (25(OH)D increase of 5.63 ng/mL versus placebo in the combined arm, P equals 0.001) with no differences in bone turnover or glycemic markers across arms, but did not report a magnesium biomarker outcome for the vitamin-D-alone arm, so it cannot confirm or refute a magnesium-lowering effect of cholecalciferol monotherapy; this is recorded as a genuine data gap rather than a null finding. A separate title-only source (see access note below) specifically addressing short-term high-dose vitamin D and mineral homeostasis in healthy young adults could not be opened during this review.
  • At-risk subgroups: Patients with baseline magnesium insufficiency (common in older adults, alcohol use disorder, malabsorption, or chronic diuretic use) are the population in which the cofactor-utilization theory would most plausibly matter, since they have the least reserve if repletion does increase magnesium demand; this remains theoretical for cholecalciferol specifically.
  • Counter-evidence on record: The Vanderbilt 2x2 factorial trial's own direction, magnesium status predicting the vitamin D metabolite response rather than the reverse, is the strongest empirical evidence located, and runs counter to a "cholecalciferol depletes magnesium" framing; per this protocol's direction check, that relationship is better filed as magnesium status affecting the drug's own metabolism, not as cholecalciferol depleting magnesium, and is disclosed here rather than used to inflate this entry's grade.

Regulatory status

Not addressed in either prescription-strength label reviewed; no magnesium interaction is labeled for cholecalciferol.

Population evidence

A nutrient-interaction review (Advances in Nutrition family, ScienceDirect) states magnesium functions as "a cofactor for vitamin D biosynthesis, transport, and activation," specifically for 25-hydroxylase, 1-alpha-hydroxylase, and 24-hydroxylase, and that magnesium deficiency itself leads to reduced 1,25-dihydroxyvitamin D and impaired parathyroid hormone response (Tier C, general vitamin D activation, not cholecalciferol-dosing specific). A double-blind, 2x2 factorial randomized trial at Vanderbilt University Medical Center (nested in the Personalized Prevention of Colorectal Cancer Trial), 180 analyzed participants (87 magnesium, 93 placebo), ages 40 to 85, tested customized magnesium dosing (mean 205.5 mg per day) against placebo for 12 weeks and measured, not intervened on, endogenous 25(OH)D3 and 24,25(OH)2D3; the effect of magnesium on vitamin D metabolites was dose-dependent and bidirectional by baseline 25(OH)D (increasing 25(OH)D3 by 2.79 ng/mL at low baseline status, P equals 0.03, but decreasing it by 6.87 ng/mL at higher baseline status, P equals 0.002). Cholecalciferol itself was not the administered intervention in this trial; it was the measured outcome. Tier B/C for the cholecalciferol-specific question.

Mechanism

Named for magnesium's role as an enzymatic cofactor in vitamin D activation and catabolism; not established in the reverse direction, that is, no named mechanism was located by which cholecalciferol supplementation itself depletes magnesium, only the general and plausible idea that increased hydroxylase throughput during high-dose repletion could increase magnesium utilization.

Counter-evidence held on record

This is a theoretical, mechanism-only concern with the empirical evidence actually pointing the other way (magnesium status shaping the vitamin D response). Do not present this as an established reason to routinely add magnesium supplementation during cholecalciferol therapy; a clinician may reasonably check magnesium in a patient with other risk factors for deficiency, but no dose of magnesium is recommended here.

The five body-system areas

Each finding is counted once, in a single area. Where a study is mentioned in a second area it is context only.

Mitochondrial Burden

Each finding below is counted once, in this area only.

Mitochondrial burden, protective at repletion, impaired in deficiency

Yellow — Low

Direction: reverse direction (as labelled in the source)

Correcting vitamin D deficiency with cholecalciferol improved skeletal muscle mass and strength in a six month human randomized trial, and companion animal and cell work from the same research program links vitamin D status to mitochondrial complex activity and biogenesis signaling; this is a protective, reverse-direction finding, not a depletion effect.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, protective/reverse direction, human RCT plus mechanistic data

Limits on what this shows

  • Key negative/null findings: The human trial measured muscle mass and grip strength, not direct mitochondrial respirometry or complex activity in human tissue; the strongest mitochondrial-mechanism data (respiration, complex activity) come from the rat and cell models, not from measurements in the human participants who received cholecalciferol, which is why this entry is graded Tier B overall for the mitochondrial mechanism specifically rather than Tier A.
  • At-risk subgroups: Older adults with diagnosed vitamin D deficiency and pre-sarcopenia are the population in which this protective signal was demonstrated; it has not been tested in vitamin D replete individuals, where no comparable benefit would be expected.
  • Counter-evidence on record: None found contradicting the direction of this finding for cholecalciferol; no source in this review reported cholecalciferol impairing mitochondrial function at any dose.

Regulatory status

Not addressed in either prescription-strength label reviewed; mitochondrial parameters are not part of cholecalciferol's clinical monitoring.

Population evidence

Communications Biology, 2022, mixed human, animal, and cell study. Human interventional arm: 115 elderly, pre-sarcopenic adults (mean age 73.3 years) with vitamin D deficiency (25(OH)D under 20 ng/mL), randomized, double-blind, cholecalciferol 10,000 IU three times weekly (roughly 4,285 IU per day average, a supraphysiologic prescription-range regimen) versus placebo for six months; appendicular lean mass increased 0.57 plus or minus 0.09 kg with supplementation versus 0.07 plus or minus 0.05 kg with placebo (P less than 0.001), and grip strength increased 0.85 plus or minus 0.31 kg versus 0.09 plus or minus 0.20 kg (P less than 0.001). Companion rat model (9 month dietary vitamin D depletion, 20 male Wistar rats) found state 3 mitochondrial respiration reduced 20 to 30% across substrates and complex I, III, and IV activities reduced 45%, 31%, and 52% respectively in deficient animals, with PGC1alpha, NRF1, and NRF2 gene expression markedly downregulated; muscle-specific inducible VDR knockout mice showed reduced citrate synthase activity (26%) and impaired mitochondrial biogenesis markers. Cholecalciferol was directly the compound administered in the human arm. Tier A for the human muscle-mass and strength outcome; Tier B for the mitochondrial-complex mechanism, which was measured in animals and cells, not directly in the human trial participants.

Mechanism

Named: vitamin D receptor signaling supports mitochondrial biogenesis via PGC1alpha, NRF1, and NRF2 pathways and maintains electron transport chain complex I through IV activity; in cultured myotubes, 1,25(OH)2 vitamin D3 increased complex I through IV activities and citrate synthase activity (29 to 37%) in a dose-dependent manner.

Counter-evidence held on record

This is a benefit of correcting diagnosed deficiency in an older, pre-sarcopenic population, not evidence that cholecalciferol should be used as a general mitochondrial enhancer in vitamin D replete people. Do not extrapolate the animal complex-activity data directly to expected human effect size.

Oxidative Stress

Each finding below is counted once, in this area only.

Oxidative stress, modest protective signal in meta-analysis, null in the largest single drug-specific trial

Yellow — Low

See study details

A systematic review and meta-analysis of vitamin D supplementation trials found small but statistically significant reductions in malondialdehyde and increases in total antioxidant capacity, while the largest single cholecalciferol-specific randomized trial located in this review found no significant effect on the same lipid-peroxidation marker.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, protective/mixed direction

Limits on what this shows

  • Key negative/null findings: The largest cholecalciferol-specific trial located in this review was genuinely null for its primary lipid-peroxidation marker (malondialdehyde, P equals 0.884) despite very high weekly doses in the deficient subgroup, and its one significant marker (advanced oxidation protein products) lost significance by 6 months, a real, disclosed null result rather than an absence of data.
  • At-risk subgroups: Not established; available drug-specific human data are limited to a type 2 diabetes, metformin-treated population.
  • Counter-evidence on record: The cholecalciferol-specific trial's null malondialdehyde result stands as direct counter-evidence to a strong antioxidant claim, even though the broader pooled meta-analysis found a small significant effect; this entry is graded on the more conservative, drug-specific null alongside the class-level pooled signal.

Regulatory status

Not addressed in either prescription-strength label reviewed.

Population evidence

Systematic review and meta-analysis (ScienceDirect, cited as covering 13 to 17 randomized clinical trials depending on the outcome analyzed) found malondialdehyde standardized mean difference of negative 0.40 (95% CI negative 0.60 to negative 0.21, P less than 0.001) and total antioxidant capacity standardized mean difference of positive 0.54 (95% CI 0.29 to 0.79, I squared equals 65.4%, P equals 0.001) favoring vitamin D supplementation; the authors' own conclusion states the effect "may not be clinically significant." Tier A, pooled trials, though not all confirmed as cholecalciferol-specific in this review. A directly cholecalciferol-specific, prospective, randomized, open-label trial (130 enrolled, type 2 diabetes patients on metformin, 6 months, weekly cholecalciferol oil drops, 50,000 IU per week for deficient patients for 3 months then 14,000 IU per week, 14,000 IU per week throughout for non-deficient patients) found no significant group difference in malondialdehyde (P equals 0.884) or the TG/TBARS index, a significant but non-sustained reduction in advanced oxidation protein products at 3 months only (group effect P equals 0.047), and no significant difference in C-reactive protein (P equals 0.669). Cholecalciferol directly administered in this trial's cohort. Tier A.

Mechanism

Proposed antioxidant and anti-inflammatory genomic vitamin D receptor signaling at therapeutic to supraphysiologic exposure; not established at the level of a specific enzyme or pathway in the cholecalciferol-specific trial cited.

Counter-evidence held on record

Do not present cholecalciferol as an antioxidant supplement. The best-controlled, cholecalciferol-specific trial located in this review was null for its primary oxidative-stress marker even at high weekly doses.

Copper and Iron Balance

Copper and iron are assessed separately. Nothing here is counted twice.

Iron, hepcidin-mediated improvement in utilization, not a stored-iron effect

Yellow — Low

Direction: reverse direction (as labelled in the source)

A single high dose of cholecalciferol substantially suppressed circulating hepcidin, the hormone that restricts dietary iron absorption and release from stores, in a placebo-controlled human trial, and a separate pooled analysis found vitamin D supplementation improved transferrin saturation and overall iron status without significantly changing ferritin.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, protective/reverse direction, dose-dependent

Limits on what this shows

  • Key negative/null findings: Ferritin was consistently unchanged across both the single-dose pilot trial and the larger pooled analysis, meaning this is specifically a utilization or mobilization signal, not evidence that cholecalciferol builds iron stores; a companion commentary on the pooled meta-analysis argues the dose used across included trials varied widely and that "high-dose vitamin D is required for hepcidin suppression," which is consistent with the null-dose, low-dose trials likely diluting the pooled hemoglobin-related effect (see Overlap map, Oxygen delivery/utilization).
  • At-risk subgroups: Not firmly established; the mechanism would plausibly matter most in patients with anemia of inflammation or chronic disease, where elevated hepcidin already restricts iron utilization, though the pilot trial cited was in healthy adults.
  • Counter-evidence on record: None found contradicting the hepcidin-suppression direction; the main limitation is that ferritin and hemoglobin outcomes do not move as consistently as hepcidin itself across the available trials.

Regulatory status

Not addressed in either prescription-strength label reviewed; iron parameters are not part of cholecalciferol's labeled monitoring.

Population evidence

Pilot, double-blind, placebo-controlled trial (ScienceDirect, Clinical Nutrition family), 28 healthy adults aged 18 to 65, over 70% vitamin D deficient at baseline, single oral 250,000 IU cholecalciferol dose versus placebo, measured at 1 week. Hepcidin fell 73% from baseline in the vitamin D group (geometric mean ratio 0.27, 95% CI 0.11 to 0.62, P equals 0.005) versus no significant change in placebo (geometric mean ratio 0.73, 95% CI 0.49 to 1.09, P equals 0.11); ferritin and inflammatory cytokines (IL-1beta, IL-6, IL-8, MCP-1) did not change significantly in either group. Cholecalciferol directly administered. Tier A. A 14-trial, 1,385-participant meta-analysis (Nutrition Journal, Springer) found transferrin saturation improved with vitamin D supplementation (mean difference 1.54, 95% CI 0.31 to 2.76, P equals 0.01) and overall iron status improved (standardized mean difference 0.24, P equals 0.002), while ferritin did not change significantly (standardized mean difference negative 0.01, 95% CI negative 0.20 to 0.18, P equals 0.91). Tier A, pooled, not all confirmed cholecalciferol-specific across every included trial.

Mechanism

Named: vitamin D receptor signaling suppresses hepatic hepcidin transcription, and hepcidin is the primary hormonal regulator restricting dietary iron absorption and macrophage iron release; suppressing it increases iron availability for erythropoiesis without necessarily changing stored iron (ferritin).

Counter-evidence held on record

This is a hormonal-utilization signal at a high single dose (250,000 IU) in healthy adults, not proof that cholecalciferol treats iron-deficiency anemia. Do not present this as a substitute for standard iron-deficiency evaluation and treatment.

Copper

Not graded — disclosed evidence gap

See study details

Copper

Full detail and limits

What the grade means here: Nothing has been measured here, so this finding cannot be graded. That does not establish either safety or harm, and it is not the same as a White result. UNGRADED

Limits on what this shows

  • Why no grade: Dual condition met: no Tier B or C evidence of a cholecalciferol-specific mechanism affecting copper status was found, and no circulating consumer claim that cholecalciferol depletes, retains, or otherwise affects copper status was found in this review. This is a genuine literature gap for the drug-nutrient relationship specifically, not a finding of safety, and is graded ungraded only after the multi-channel effort described below.

Channels tried

WebSearch queries on vitamin D and copper status, ceruloplasmin, and trace mineral interactions were run before this session's WebSearch budget (200 calls) was exhausted; results surfaced only tangential material (a preterm-infant assay comparison study not involving cholecalciferol dosing, the general NIH copper fact sheet, and non-peer-reviewed alternative-medicine content not usable at any tier). After the WebSearch budget was exhausted, WebFetch attempts were made against PubMed and PubMed Central directly (bot-verification challenge on every attempt), the NCBI eutils API (blocked by that host's robots.txt), the Europe PMC REST API (HTTP 429 rate-limited, then the europepmc.org web interface separately blocked by robots.txt), the Semantic Scholar API (HTTP 429 rate-limited), and a plain-text search engine proxy, DuckDuckGo, as a fallback discovery channel (blocked by that host's robots.txt before any results could be read). No channel that responded returned drug-specific copper evidence for cholecalciferol. This is disclosed as a tooling-limited outcome layered on top of a genuine content gap in what WebSearch did surface; a later revision with different tooling access should re-run this category before assuming the gap is purely one of literature non-existence.

Context to disclose

Some multivitamin and bone-health combination products co-formulate vitamin D3 with copper alongside calcium, magnesium, and zinc for general nutrition marketing purposes; this reflects product formulation choices, not a documented pharmacological interaction between cholecalciferol and copper status, and is not evidence for a graded entry.

Gut Microbiome Risk

Each finding below is counted once, in this area only.

Gut microbiome risk, real compositional shift, direction mixed rather than clearly harmful

Yellow — Low

See study details

A twelve week, placebo-controlled monotherapy trial found cholecalciferol supplementation increased gut microbiota community stability and shifted several taxa, with the direction of individual taxonomic changes mixed rather than uniformly favorable or unfavorable.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, mixed direction, monotherapy RCT

Limits on what this shows

  • Key negative/null findings: Alpha diversity, the most commonly cited general marker of a "healthy" microbiome, did not significantly change with treatment; the placebo group's diversity decline over the study period suggests some of the apparent treatment effect on stability may reflect placebo-group drift as much as a treatment-driven improvement.
  • At-risk subgroups: Not established; this trial enrolled healthy adults, not a population selected for gut dysbiosis or gastrointestinal disease.
  • Counter-evidence on record: The depletion of Faecalibacterium, a genus generally associated with anti-inflammatory short-chain fatty acid production in other microbiome literature, is a plausible unfavorable-direction signal sitting alongside the enrichment of Bifidobacterium, generally considered favorable; the trial's own framing emphasizes increased stability rather than a uniformly beneficial shift, and this review found no basis to call the net direction clearly protective or clearly harmful.

Regulatory status

Not addressed in either prescription-strength label reviewed.

Population evidence

Double-blind, randomized, placebo-controlled trial (Microbiology Spectrum, American Society for Microbiology), 43 enrolled, 41 completed (21 vitamin D, 22 placebo), healthy adults aged 18 to 53, cholecalciferol 4,000 IU per day for 12 weeks as a gummy taken with the largest daily meal, serum 25(OH)D rising from 39.9 plus or minus 15.2 to 72.6 plus or minus 27.9 ng/mL (P less than 0.0001). Cholecalciferol directly administered as monotherapy, a stronger evidence base for isolating the drug's independent effect than several other entries in this dossier. Alpha diversity (Shannon index, Faith's phylogenetic diversity, richness) did not change significantly within the treatment group, while the placebo group showed significant reductions at multiple timepoints (P less than 0.05). Beta diversity, community structure over time, showed significantly increased compositional similarity in the treatment group (P less than 0.0001), with microbiota stability inversely correlated with the rise in serum 25(OH)D (R equals negative 0.52, P equals 0.019). Acutely enriched taxa included Bifidobacterium and Anaerostipes; persistently enriched, Erysipelotrichaceae UCG-003; acutely depleted, Bacteroides and Faecalibacterium; persistently depleted, Prevotella and Eubacterium coprostanoligenes. Tier A.

Mechanism

Not fully established; broader vitamin D receptor biology is proposed as a modulator of gut epithelial tight junctions and antimicrobial peptide expression, providing class-level plausibility, but the specific mechanism driving these particular taxonomic shifts was not elucidated in the cited trial.

Counter-evidence held on record

Do not present this as evidence that cholecalciferol clearly improves or clearly harms gut microbiome health; the taxonomic shifts run in both directions by conventional interpretation, and clinical significance of the stability finding is not established.

Oxygen and ATP Output

Oxygen delivery and ATP production are assessed separately. Nothing here is counted twice.

ATP production, muscle bioenergetics improved with repletion, direct ATP flux not measured

Yellow — Low

Direction: reverse direction (as labelled in the source)

The same human trial and mechanistic program cited under mitochondrial burden reports muscle mass and strength gains and cellular citrate synthase and electron transport chain activity consistent with improved ATP-generating capacity during cholecalciferol repletion of deficiency, but no source located in this review directly measured ATP or phosphocreatine flux in human muscle.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, protective/reverse direction, proxy measures only

Limits on what this shows

  • Key negative/null findings: No direct ATP or phosphocreatine-recovery flux assay was located and successfully opened in this review for cholecalciferol; the human trial's functional outcomes (muscle mass, grip strength) are real and statistically significant but are downstream, multifactorial measures, not a specific ATP-production readout, a genuine limitation on how strongly this entry can be graded.
  • At-risk subgroups: Not established beyond the deficient, pre-sarcopenic older-adult population in the cited trial.
  • Counter-evidence on record: None found contradicting the direction; the limitation here is measurement directness, not a competing finding.

Regulatory status

Not addressed in either prescription-strength label reviewed.

Population evidence

Same Communications Biology 2022 source as the Mitochondrial burden entry (see Overlap map): human trial (115 elderly, vitamin D deficient, pre-sarcopenic adults, cholecalciferol 10,000 IU three times weekly for six months) showing significant gains in appendicular lean mass and grip strength versus placebo, plus cell-model citrate synthase activity increases of 29 to 37% with 1,25(OH)2 vitamin D3 treatment, an enzyme central to the tricarboxylic acid cycle that feeds oxidative ATP synthesis. A separate title-only source specifically using 31-phosphorus magnetic resonance spectroscopy to measure muscle phosphocreatine and ATP metabolites in relation to vitamin D supplementation could not be opened during this review (see access note).

Mechanism

Proposed via the same PGC1alpha and mitochondrial biogenesis pathway described under Mitochondrial burden; citrate synthase and electron transport chain complex activity are accepted proxies for oxidative ATP-generating capacity, but are not a direct ATP measurement.

Counter-evidence held on record

Do not present this as evidence that cholecalciferol directly boosts cellular ATP output; the underlying data are proxy enzyme-activity and functional muscle measures in a deficient population, not a direct energy-flux measurement, and this is not a basis for treating fatigue in vitamin D replete people.

Oxygen delivery / utilization, mostly null on hemoglobin overall, dose- and population-dependent subgroup signals

Yellow — Low

See study details

Pooled across 14 randomized trials, vitamin D supplementation had no significant overall effect on hemoglobin, but the pooled analysis's own subgroup breakdown and a separate high-dose bolus trial in critically ill patients both suggest the null overall result may mask a real, dose- and population-dependent effect in opposite directions.

Full detail and limits

What the grade means here: Mechanistic plausibility only (Tier B), or class extrapolation (Tier C) with no drug-specific human status data; also used for context flags and interactions running the other direction. YELLOW, mixed direction, subgroup detail not independently verified

Limits on what this shows

  • Key negative/null findings: The overall pooled result is a genuine null (P equals 0.95) with substantial heterogeneity (I squared equals 82%), meaning any subgroup signal should be treated cautiously; a companion published commentary on this same meta-analysis explicitly argues the null overall finding is misleading because it combines widely varying doses and populations, some without baseline anemia.
  • At-risk subgroups: The meta-analysis's own subgroup categories (chronic kidney disease, shown as harm-direction; critically ill, shown as strong benefit-direction) are noted here as a flagged, unresolved signal rather than a verified, bounded finding, because this review could not open and individually cohort-check the specific primary studies underlying each subgroup estimate.
  • Counter-evidence on record: The overall null result is itself the main counter-evidence against any blanket claim that cholecalciferol raises or lowers hemoglobin; this entry is graded yellow rather than orange specifically because the CKD subgroup harm signal could not be traced to and verified against its individual constituent primary studies within this review's access constraints.

Regulatory status

Not addressed in either prescription-strength label reviewed; hematologic parameters are not part of cholecalciferol's labeled monitoring.

Population evidence

Systematic review and meta-analysis (Nutrition Journal, Springer), 14 randomized controlled trials, 1,385 participants aged 17.5 to 68, publications from 2000 to 2019. Pooled hemoglobin standardized mean difference was 0.01 (95% CI negative 0.28 to 0.29, P equals 0.95, I squared equals 82%), a null overall result with high heterogeneity. The same review's subgroup breakdown reported standardized mean differences of negative 1.07 in chronic kidney disease patients (a harm-direction signal), positive 3.85 in critically ill adults (a large benefit-direction signal), and near zero in healthy adults, anemic patients, heart failure patients, and hypertensive patients. Separately, a pilot double-blind randomized placebo-controlled trial in mechanically ventilated critically ill adults (100,000 IU daily for 5 days, 500,000 IU total) reported mean hemoglobin of 11.25 g/dL in the vitamin D group versus 6.7 g/dL in placebo. Cholecalciferol directly administered in the critically ill bolus trial; the meta-analysis's constituent trials were not individually re-verified for cholecalciferol-specificity in this review.

Mechanism

Proposed via hepcidin suppression at high dose (see Iron entry, shared evidence base, disclosed in Overlap map), which would raise hemoglobin by improving iron availability for erythropoiesis; no mechanism was located explaining the CKD subgroup's negative-direction signal, and disease progression is a plausible competing explanation this review cannot exclude with the available pooled-level data.

Counter-evidence held on record

Do not present cholecalciferol as reliably raising hemoglobin; the large pooled result is null. The chronic kidney disease subgroup signal is flagged, not confirmed, and should prompt monitoring rather than a supplementation claim, while the critically ill bolus-dose benefit is a distinct, high-acuity, high-dose clinical context that does not generalize to routine outpatient repletion.

Claims checked and not supported

These circulate online for this medication. They are listed here only so they can be answered, never as findings, and they are not graded.

A claim with no supporting evidence is not necessarily disproven. Where evidence actually argues against a claim, that is stated below.

  • Over-the-counter and prescription-strength vitamin D3 carries no real toxicity risk because it is "just a vitamin," unlike a synthetic drug

    Where it comes from: General wellness and supplement-marketing framing of vitamin D as inherently benign because it is naturally produced by the skin

    Why it fails: A published review of case reports (Nutrients, 2018) covering 13 source articles and more than 82 documented cases found serum calcium as high as 23.1 mg/dL from vitamin D dosing ranging from prescribed 50,000 IU per day regimens continued too long to massive unintentional exposures, with outcomes including acute kidney injury; both prescription-strength labels reviewed for this dossier list hypercalcemia as a contraindication and require calcium and phosphorus monitoring at least every two weeks. The drug's own case-report and regulatory record directly contradicts the "risk free because natural" framing.

  • Vitamin D3 (cholecalciferol) acts as fast as, and is pharmacologically interchangeable with, calcitriol (active vitamin D) for correcting hypocalcemia or hyperparathyroidism

    Where it comes from: Consumer conflation of "vitamin D" as a single interchangeable category across its precursor and fully activated forms

    Why it fails: Cholecalciferol's own label states a 10 to 24 hour lag before initial action and effects persisting two or more months after treatment stops, reflecting its two-step hepatic-then-renal activation requirement and extensive adipose storage; this project's calcitriol dossier documents calcitriol's labeled 5 to 8 hour terminal half-life and rapid, titratable onset as the already-activated terminal hormone. The two forms have materially different, label-documented pharmacokinetic profiles and are not interchangeable for situations requiring fast correction.

  • Vitamin D3 supplementation reliably raises hemoglobin and treats low energy or fatigue by improving blood oxygen-carrying capacity for everyone

    Where it comes from: General wellness content linking vitamin D repletion to improved energy and "blood health"

    Why it fails: A 14-trial, 1,385-participant meta-analysis found no significant overall effect of vitamin D supplementation on hemoglobin (standardized mean difference 0.01, 95% CI negative 0.28 to 0.29, P equals 0.95). The drug's own best available pooled evidence directly contradicts an unqualified claim that supplementation raises hemoglobin across the board; the narrower, dose- and population-bounded signal that does exist is addressed separately and non-promotionally under the graded Oxygen delivery/utilization entry.

All references used above
  1. DECALCITROL, CHOLECALCIFEROL (VITAMIN D3) 1.25 mg tablets (50,000 units), full labeling — FDA-registered labeling via DailyMed. Cited for onset lag, contraindications, monitoring requirements (calcium and phosphorus every two weeks), thiazide interaction, mineral oil interaction, storage/persistence of effect, and hepatic impairment caution.
  2. VITAMIN D3 1.25 MG (50,000 IU), dietary supplement labeling — Labeling via DailyMed for a second prescription-strength 50,000 IU cholecalciferol product. Cited for contraindications, thiazide diuretic toxicity warning, and absence of documented CYP450 or antacid/bile-acid-sequestrant interaction language on this label.
  3. Cholecalciferol (oral route), clinical interaction listing — Mayo Clinic patient/clinician drug-interaction reference. Cited for the phenytoin, fosphenytoin, and erdafitinib interaction flags and their documented direction (these agents affecting cholecalciferol's clearance).
  4. Cholecalciferol, Wikipedia — Used only for ATC code confirmation (A11CC05) and for the adipose-storage and slow-release pharmacokinetic description cross-checked against the DailyMed labels. Not used as a clinical evidence source for any graded claim.
  5. NIH Office of Dietary Supplements, Vitamin D Health Professional Fact Sheet — Reference for the Tolerable Upper Intake Level of nutritional vitamin D (100 mcg, 4,000 IU per day for adults, applying to general nutritional intake rather than supervised prescription-strength dosing), hypercalcemia threshold (total calcium above 11.1 mg/dL), and the toxicity-associated serum 25(OH)D threshold (above 150 ng/mL).
  6. NIH Office of Dietary Supplements, Calcium Health Professional Fact Sheet — Reference for the calcium Tolerable Upper Intake Level (2,500 mg per day ages 19 to 50, 2,000 mg per day above age 50), cited in Scope and Limits.
  7. NIH Office of Dietary Supplements, Magnesium Health Professional Fact Sheet — Reference for the supplemental magnesium Tolerable Upper Intake Level (350 mg per day for adults), cited in Scope and Limits and the Magnesium entry's framing caution.
  8. NIH Office of Dietary Supplements, Vitamin K Health Professional Fact Sheet — Reference confirming no Tolerable Upper Intake Level has been established for vitamin K, the Adequate Intake values (120 mcg per day men, 90 mcg per day women), and the matrix Gla protein/vascular calcification mechanism cited in the Vitamin K entry.
  9. "Development of Vitamin D Toxicity from Overcorrection of Vitamin D Deficiency: A Review of Case Reports." Nutrients. 2018;10(8):953. — Systematic review of 13 source articles, more than 82 documented cases of vitamin D toxicity, doses from prescribed 50,000 IU per day regimens to manufacturing-error and massive unintentional exposures, serum calcium up to 23.1 mg/dL. Cholecalciferol/vitamin D directly the agent in every case reviewed. Tier A.
  10. "Essential Nutrient Interactions: Does Low or Suboptimal Magnesium Status Interact with Vitamin D and/or Calcium Status?" Advances in Nutrition family journal, ScienceDirect. — Narrative review of magnesium's cofactor role in vitamin D activation (25-hydroxylase, 1-alpha-hydroxylase, 24-hydroxylase) and calcium-to-magnesium ratio literature. Class-level/mechanistic reference, not cholecalciferol-dosing specific. Tier C for the cholecalciferol-specific question.
  11. "Magnesium status and supplementation influence vitamin D status and metabolism: results from a randomized trial." American Journal of Clinical Nutrition, ScienceDirect mirror. — Double-blind, 2x2 factorial RCT, Vanderbilt University Medical Center, n=180, magnesium supplementation (mean 205.5 mg per day) versus placebo, 12 weeks, measuring endogenous 25(OH)D3 and 24,25(OH)2D3 as outcomes. Magnesium, not cholecalciferol, was the administered intervention. Tier B/C for the cholecalciferol-specific direction question; cited to establish the empirical direction of the magnesium-vitamin D relationship.
  12. "Combined vitamin D and magnesium supplementation does not influence markers of bone turnover or glycemic control: A randomized controlled clinical trial." ScienceDirect. — Randomized, double-blind, placebo-controlled trial, n=78 completers, cholecalciferol 1,000 IU alone versus cholecalciferol plus magnesium glycinate 360 mg versus placebo, 12 weeks. Cholecalciferol directly administered; magnesium biomarker outcome not reported for the vitamin-D-alone arm in the content retrieved. Tier A for vitamin D repletion confirmation, disclosed data gap for the magnesium-specific question.
  13. "Effects of Short-term High-dose Vitamin D Supplementation on Mineral Homeostasis in Healthy Young Adults." (PMC13133833) — Title and PMC identifier located via search; directly on point for the Magnesium entry but full text could not be opened despite repeated attempts. Not used as an independent line of evidence; disclosed for transparency only.Full text could not be opened: pmc.ncbi.nlm.nih.gov returned a bot-verification challenge on every attempt during this review.
  14. "Effects of vitamin K2 and D supplementation on coronary artery disease in men: A randomized controlled trial" (AVADEC trial substudy). JACC: Advances, ScienceDirect mirror. — Multicenter, double-blind RCT, four Danish hospitals, n=304 completers, elderly men with elevated calcification scores, vitamin K2 720 mcg per day plus vitamin D3 25 mcg (1,000 IU) per day versus placebo, 24 months. Cholecalciferol directly administered as part of the combined regimen; no vitamin-D-alone arm. Tier A for the combination claim, not for an isolated cholecalciferol effect.
  15. "High-dose vitamin D3 reduces circulating hepcidin concentrations: A pilot, randomized, double-blind, placebo-controlled trial in healthy adults." Clinical Nutrition, ScienceDirect mirror. — RCT, n=28, single oral 250,000 IU cholecalciferol dose versus placebo, 1 week. Cholecalciferol directly administered. Tier A. Hepcidin fell 73% (P=0.005); ferritin unchanged.
  16. "Randomized control trial of moderate dose vitamin D alters microbiota stability and metabolite networks in healthy adults." Microbiology Spectrum. — Double-blind, placebo-controlled RCT, n=41 completers, cholecalciferol 4,000 IU per day for 12 weeks, healthy adults. Cholecalciferol directly administered as monotherapy. Tier A.
  17. "Vitamin D status modulates mitochondrial oxidative capacities in skeletal muscle: role in sarcopenia." Communications Biology. 2022. — Mixed human RCT (n=115, cholecalciferol 10,000 IU three times weekly for 6 months), rat depletion model, VDR-knockout mouse model, and cell-culture study. Cholecalciferol directly administered in the human arm. Tier A for human muscle mass/strength outcomes, Tier B for mitochondrial-complex mechanism data (measured in animals and cells).
  18. "Effect of vitamin D supplementation on muscle energy phospho-metabolites: a 31P magnetic resonance spectroscopy-based pilot study." (PMID 24679100) — Title located via search; directly on point for the ATP production entry but full text could not be opened. Not used as an independent line of evidence; disclosed for transparency only.Full text could not be opened: the ResearchGate mirror returned an HTTP 429 rate-limit response on the only attempt made during this review.
  19. "The Effects of Vitamin D Supplementation on Metabolic and Oxidative Stress Markers in Patients With Type 2 Diabetes: A 6-Month Follow Up Randomized Controlled Study." Frontiers in Endocrinology. 2021. — Prospective, randomized, controlled, open-label trial, n=130 enrolled (49 vitamin D completers, 65 metformin-only completers), type 2 diabetes on metformin, weekly cholecalciferol oil drops (50,000 IU per week for 3 months then 14,000 IU per week for deficient patients; 14,000 IU per week throughout for non-deficient patients), 6 months. Cholecalciferol directly administered. Tier A. Null result for malondialdehyde (P=0.884).
  20. "The effect of vitamin D supplementation on oxidative stress parameters: A systematic review and meta-analysis of clinical trials." ScienceDirect. — Systematic review and meta-analysis, described in the abstract as covering 13 clinical trials (17 referenced elsewhere in the paper's discussion), pooled malondialdehyde and total antioxidant capacity outcomes. Not all constituent trials independently confirmed as cholecalciferol-specific in this review. Tier A/C blend, treated conservatively alongside the cholecalciferol-specific Frontiers trial above.
  21. "The effect of vitamin D supplementation on hemoglobin concentration: a systematic review and meta-analysis." Nutrition Journal. Springer Nature. — Systematic review and meta-analysis, 14 RCTs, n=1,385, publications 2000 to 2019. Pooled hemoglobin null (P=0.95); subgroup estimates by population (chronic kidney disease, critically ill, healthy, anemic, heart failure, hypertensive). Constituent trials not individually re-verified for cholecalciferol-specificity in this review. Tier A for the pooled outcome, subgroup detail treated as an unverified flag per the Oxygen delivery/utilization entry.
  22. "Vitamin D supplementation and hemoglobin: dosing matters in prevention/treatment of anemia." Nutrition Journal. Springer Nature. — Invited commentary responding to the meta-analysis above, citing the critically ill high-dose bolus trial (100,000 IU daily for 5 days, mean hemoglobin 11.25 g/dL vitamin D versus 6.7 g/dL placebo) as evidence that dose and population drive heterogeneity in the pooled null result.